Bound or Complex Prostate-specific Antigen (cPSA) (K133) [Back]
|
 |
| RISK ASSESSMENT VALUE: |
Aid in the detection of prostate cancer.
|
| NORMAL RESULTS: |
Complex PSA 0-4 ng/ml
Total PSA 0-4 ng/ml
% Free PSA 15-75%
|
| ABNORMAL RESULTS: |
INcreased Serum levels due to benign prostatic hypertrophy, prostitis or adrenocarcinoma of prostate.
|
| ADDITIONAL TESTS: |
Total PSA
% Free PSA
DRE
|
| SAMPLE NEEDED: |
Separated serum from red or mottled-stopper tube.
|
| SAMPLE STABILITY: |
48 hours refrigerated; indefinitely when frozen. Avoid repeated freezing and thawing.
|
| METHOD & INSTRUMENT: |
Immunoassay.
|
| INTERFERING FACTORS: |
Less than a 5% change in results due to hemolysis (<500 mg/dL of hemoglobin), lipemia (<1000 mg/dL of triglycerides), icterus (<40 mg/dL of bilirubin) and proteinuria (<12.5 g/dL of protein).
Individuals undergoing prostate manipulation procedures (prostate massage, rectal examination, prostatectomy or biopsy).
|
| PURPOSE: |
PSA complexed with ACT comprises a higher proportion of PSA in men with prostate cancer than men withot cancer. Total PSA along with Complex PSA provide additional information in the differential diagnosis of prostate cancer.
|
| PROFILE INCLUDES: |
|
| RISK RANGE & UNITS: |
Complex PSA 0-4 ng/ml
Total PSA 0-4 ng/ml
% Free PSA 15-75 %
|
Home
